[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiani Wu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100538218","tavns-improves-the-symptoms-of-patients-with-moderate-to-severe-cpcpps-100538218",false,"NCT06287970","TaVNS Improves the Symptoms of Patients With Moderate to Severe CP\u002FCPPS","Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Moderate to Severe Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (TASC-P Trial): a Randomized, Sham Controlled Trial.","Inclusion Criteria:\n\n* Consistent with the diagnostic criteria of CP\u002FCPPS of EAU or CAU, the clinical manifestations were recurrent and persistent prostate pain accompanied by abnormal urination and psychiatric symptoms, without infection or other obvious pathological conditions. The pain symptoms were mainly manifested as pain in the surrounding tissues centered on the prostate, and pain, swelling or discomfort in the scrotum, testis, lower abdomen, perineum, lumbosacral area, and medial thigh. Abnormal urination was characterized by frequent urination, urgent urination, urination pain, urethral burning, residual urination or white discharge from the urethra at the end of urination or defecation in the morning. The neuropsychiatric symptoms included dizziness and tinnitus, insomnia and dreams, anxiety and depression, and even impotence, premature ejaculation, and spermatorrhea. Symptoms lasting more than 3 months in the last six months\n* 18 ≤ Age ≤ 50 years old\n* NIH-CPSI ≥15 (patients with moderate to severe CP\u002FCPPS)\n* Signed informed consent and voluntarily participated in the trial\n\nExclusion Criteria:\n\n* Patients with other diseases that cause urinary symptoms were excluded: Such as benign prostatic hyperplasia, testicular and epididymal and spermatic cord diseases, overactive bladder, neurogenic bladder, interstitial cystitis, glandular cystitis, sexually transmitted diseases, bladder tumors such as carcinoma in situ, prostate cancer, urinary male reproductive system tuberculosis, anorectal diseases, lumbar diseases, central and peripheral neuropathy, etc\n* Patients with severe diseases of the heart, liver, kidney, hematopoietic system and poor nutritional status\n* Patients with severe mental and emotional disorders, who were unable to cooperate with the study\n* Patients who have been treated with CP\u002FCPPS regimen in the past 4 weeks","MALE","18 Years","50 Years",{"count":20,"type":21},68,"ESTIMATED","INTERVENTIONAL",[24],"NA","This trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for moderate to severe chronic prostatitis\u002Fchronic pelvic pain syndrome (CP\u002FCPPS). This study is a prospective, randomized, controlled trial. A total of 68 patients with CP\u002FCPPS will be recruited. After baseline assessment, the patients will be randomized into taVNS group (n = 34) and sham-taVNS group (n = 34). The intervention of two group will last for 4 weeks with a 8-week follow-up period after the treatment. The National Institutes of Health chronic Prostatitis Symptom Score index (NIH-CPSI), International Prostate Symptom Score Scale (IPSS), European quality of Life-5 Dimensions Questionnaire (EQ-5D), self-rating anxiety Scale (SAS) and self-rating depression scale (SDS) will be assessed. The adverse events during the whole study will be recorded detailedly.",[27],"Chronic Prostatitis","RECRUITING","2025-11-22",{"date":31,"type":32},"2025-11-28","ACTUAL",{"date":34,"type":32},"2024-03-15",{"date":36,"type":21},"2027-02-18",{"name":38,"class":39},"Jiani Wu","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100583321","acupuncture-and-moxibustion-for-motor-symptoms-in-early-parkinsons-disease-100583321","NCT06874803","Acupuncture and Moxibustion for Motor Symptoms in Early Parkinson's Disease","Effect of \"Qi-Tonifying, Yang-Warming, and Water-Resolving\" Acupuncture and Moxibustion for Motor Symptom Improvement in Early Parkinson's Disease (WARMED): A Randomized Controlled Trial","WARMED","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1\\. Diagnosed with Parkinson's disease (PD) according to the 2016 Chinese 2. Diagnostic Criteria for Parkinson's Disease.\n\n3\\. Hoehn-Yahr stage \\\u003C3 (mild to moderate PD). 4. Age between 30 and 80 years (inclusive). 5. Signed informed consent indicating voluntary participation.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. Diagnosed with Parkinson-plus syndromes or other secondary parkinsonism.\n2. Prior history of deep brain stimulation (DBS) surgery.\n3. Severe cerebrovascular disease, brain trauma, or history of craniotomy.\n4. Severe dementia or psychiatric disorders that prevent cooperation with study procedures.\n5. Severe coagulation disorders.\n6. Presence of severe systemic organ dysfunction (cardiac, pulmonary, hepatic, renal, endocrine, or metabolic disorders).\n7. Pregnant or breastfeeding women.\n8. History of allergic reaction to acupuncture or moxibustion.\n9. Prior treatment with acupuncture or moxibustion within the past three months.\n10. Participation in another clinical trial within the past three months.","ALL","30 Years","80 Years",{"count":53,"type":21},60,[24],"This study evaluates the clinical effect and safety of acupuncture combined with moxibustion in improving motor symptoms of early-stage Parkinson's Disease (PD) patients, by assessing the changes in UPDRS scores. It also explores objective factors affecting the acupuncture effect and investigates the functional MRI mechanisms of acupuncture in PD treatment.",[57],"Parkinson's Disease (PD)",[59,60,61,62,63],"Acupuncture","Moxibustion","Parkinson's Disease","Motor Symptoms","Rigidity","2025-07-16",{"date":66,"type":32},"2025-07-20",{"date":68,"type":32},"2024-08-01",{"date":70,"type":21},"2026-08-31",{"name":38,"class":39},""]